MOTS-c: Promise and Limits of a Mitochondrial Peptide

The correct name is MOTS-c, short for mitochondrial open reading frame of the 12S rRNA type-c. Variants such as MOTSc or Mots-C refer to the same peptide. First described in 2015, it is a 16-amino-acid peptide encoded not in the nucleus but in mitochondrial DNA — one of a small family of so-called mitochondrial-derived peptides.

Mechanism under study

In cell and mouse studies, MOTS-c inhibits the folate cycle, leading to accumulation of AICAR and activation of AMPK, a central energy sensor. Under metabolic stress it has been reported to move to the nucleus and influence gene expression. These findings position it as a signalling molecule between mitochondria and the rest of the cell.

State of the human evidence

Rodent studies reported improved insulin sensitivity, resistance to diet-induced weight gain and better physical capacity in older animals. In humans, the evidence is mainly observational: circulating MOTS-c levels have been measured and correlated with age, exercise and metabolic markers. Correlation does not show that giving the peptide produces a benefit. As of this review, no published randomised controlled trial has demonstrated clinical efficacy or long-term safety of MOTS-c in people.

Limitations, risks and adverse effects

• Doses, routes and durations used in mice do not translate directly to humans.
• There is no systematic human safety database, so the adverse-effect profile is essentially unknown.
• Unregulated products carry risks of impurity, mislabelled content and contamination.
• AMPK activation interacts with glucose metabolism; effects in people with diabetes or on medication are untested.

Regulatory status by region

MOTS-c is not an approved medicine anywhere — not by the FDA, the EMA or the MHRA. It is an investigational research compound. Competitive athletes should note that the World Anti-Doping Agency prohibits metabolic modulators, including AMPK activators; the current Prohibited List should always be checked.

Bottom line

MOTS-c is a scientifically important discovery with an interesting mechanism, but the evidence is preclinical and observational. For background on the molecule itself, see our MOTS-c research profile; for a compound that is often confused with peptides, see our NAD+ evidence review.